Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Leiomyosarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (640
)
Soft Tissue Sarcoma (425
)
Spindle Cell Sarcoma (94
)
Osteosarcoma (54
)
Ewing Sarcoma (43
)
Rhabdomyosarcoma (34
)
Fibrosarcoma (33
)
Liposarcoma (23
)
Uterine Corpus Leiomyosarcoma (22
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
Sarcoma (640
)
Soft Tissue Sarcoma (425
)
Spindle Cell Sarcoma (94
)
Osteosarcoma (54
)
Ewing Sarcoma (43
)
Rhabdomyosarcoma (34
)
Fibrosarcoma (33
)
Liposarcoma (23
)
Uterine Corpus Leiomyosarcoma (22
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
›
Associations
(53)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HR positive
Leiomyosarcoma
HR positive
Leiomyosarcoma
nivolumab + talimogene laherparepvec
Sensitive: C3 – Early Trials
ASGCT 2023 - 3 weeks (New C3)
nivolumab + talimogene laherparepvec
Sensitive
:
C3
ASGCT 2023 - 3wk
nivolumab + talimogene laherparepvec
Sensitive: C3 – Early Trials
ASGCT 2023 - 3 weeks
nivolumab + talimogene laherparepvec
Sensitive
:
C3
ASGCT 2023 - 3 weeks - (New C3)
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Uterine Corpus Leiomyosarcoma
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
doxorubicin hydrochloride + dacarbazine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + dacarbazine
Sensitive
:
A2
doxorubicin hydrochloride + dacarbazine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + dacarbazine
Sensitive
:
A2
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
PTC596
Sensitive: B - Late Trials
PTC596
Sensitive
:
B
PTC596
Sensitive: B - Late Trials
PTC596
Sensitive
:
B
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AZD5363
Sensitive: C3 – Early Trials
AZD5363
Sensitive
:
C3
AZD5363
Sensitive: C3 – Early Trials
AZD5363
Sensitive
:
C3
Chr amplification(4)(q22.1)
Leiomyosarcoma
Chr amplification(4)(q22.1)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(3)(q14.2)
Leiomyosarcoma
Chr del(3)(q14.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(11)(q25)
Leiomyosarcoma
Chr del(11)(q25)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(2)(q14.1)
Leiomyosarcoma
Chr del(2)(q14.1)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(2)(p12)
Leiomyosarcoma
Chr del(2)(p12)
Leiomyosarcoma
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
Chr del(1)(q44)
Leiomyosarcoma
Chr del(1)(q44)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr amplification(8)(q13.2)
Leiomyosarcoma
Chr amplification(8)(q13.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr amplification(8)(q22.2)
Leiomyosarcoma
Chr amplification(8)(q22.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr amplification(13)(q13.3)
Leiomyosarcoma
Chr amplification(13)(q13.3)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr amplification(20)(p12.2)
Leiomyosarcoma
Chr amplification(20)(p12.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr amplification(4)(q26)
Leiomyosarcoma
Chr amplification(4)(q26)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
ATRX mutation
Leiomyosarcoma
ATRX mutation
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
TP53 mutation
Leiomyosarcoma
TP53 mutation
Leiomyosarcoma
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
ATRX mutation
Leiomyosarcoma
ATRX mutation
Leiomyosarcoma
dacarbazine
Resistant: C3 – Early Trials
dacarbazine
Resistant
:
C3
dacarbazine
Resistant: C3 – Early Trials
dacarbazine
Resistant
:
C3
TP53 mutation
Leiomyosarcoma
TP53 mutation
Leiomyosarcoma
dacarbazine
Resistant: C3 – Early Trials
dacarbazine
Resistant
:
C3
dacarbazine
Resistant: C3 – Early Trials
dacarbazine
Resistant
:
C3
CD70 expression
Uterine Corpus Leiomyosarcoma
CD70 expression
Uterine Corpus Leiomyosarcoma
ARX305
Sensitive: C3 – Early Trials
ARX305
Sensitive
:
C3
ARX305
Sensitive: C3 – Early Trials
ARX305
Sensitive
:
C3
AKT1 mutation + mTOR mutation
Leiomyosarcoma
AKT1 mutation + mTOR mutation
Leiomyosarcoma
CB-228
Sensitive: C3 – Early Trials
CB-228
Sensitive
:
C3
CB-228
Sensitive: C3 – Early Trials
CB-228
Sensitive
:
C3
TMB-H
Leiomyosarcoma
TMB-H
Leiomyosarcoma
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
anastrozole
Sensitive: C3 – Early Trials
anastrozole
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login